title: High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010.
abstract: BACKGROUND
  Contemporary data on patterns of antiretroviral therapy (ART) use in the United States are needed to inform efforts to improve the HIV care cascade.
  
  
  METHODS
  We conducted a cross-sectional study of patients in the Centers for AIDS Research Network of Integrated Clinical Systems cohort who were in HIV care in 2010 to assess ART use and outcomes, stratified by nadir CD4 count (≤350, 351-500, or >500 cells/mm), demographics, psychiatric diagnoses, substance use, and engagement in continuous care (≥2 visits ≥3 months apart in 2010).
  
  
  RESULTS
  Of 8633 patients at 7 sites who had ≥1 medical visit and ≥1 viral load in 2010, 94% had ever initiated ART, 89% were on ART, and 70% had an undetectable viral load at the end of 2010. Fifty percent of ART-naive patients had nadir CD4 counts >500 cells per cubic millimeter, but this group comprised just 3% of the total population. Among patients who were ART naive at the time of cohort entry (N = 4637), both ART initiation and viral suppression were strongly associated with nadir CD4 count. Comparing 2009 and 2010, the percentages of patients with viral suppression among those with nadir CD4 counts 351-500 and >500 cells per cubic millimeter were 44% vs. 57% and 25% vs. 33%, respectively. Engagement in care was the only factor consistently associated with ART use and viral suppression across nadir CD4 count strata.
  
  
  CONCLUSIONS
  Our findings suggest that ART use and viral suppression among persons in HIV care may be more common than estimated in some previous studies and increased from 2009 to 2010.
authors.affiliation: Department of Medicine, University of Washington, Seattle, WA 98104, USA. jdombrow@uw.edu
authors.forename: Julia C
authors.initials: JC
authors.lastname: Dombrowski
authors.forename: Mari M
authors.initials: MM
authors.lastname: Kitahata
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Van Rompaey
authors.forename: Heidi M
authors.initials: HM
authors.lastname: Crane
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mugavero
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Eron
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Boswell
authors.forename: Benigno
authors.initials: B
authors.lastname: Rodriguez
authors.forename: W Christopher
authors.initials: WC
authors.lastname: Mathews
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Martin
authors.forename: Richard D
authors.initials: RD
authors.lastname: Moore
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Golden
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D005260:Female; D006678:HIV / Q000187:drug effects / Q000502:physiology*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D014481:United States; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral